|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2008-12-1
|
|
pubmed:abstractText |
We assessed the efficacy of combined temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma in a phase II single-institution trial. Twenty-four patients were enrolled. Temozolomide (150 mg/m(2)/day for 7 days every other week) was administered with concomitant thalidomide (200 mg/day), and continued until unacceptable toxicity or disease progression. There were no complete responses and two (10%) partial responses. Five patients (24%) had stable disease for at least six months. Fourteen patients (67%) progressed after a median of two-month treatment. The median overall survival (twenty-two assessable patients) was 9.5 months [95% CI 7-28 months]. There were no treatment-related deaths or CTC grade 4 toxicities. Thirteen patients were dose-reduced or discontinued thalidomide due to toxicity. In conclusion, this combination of temozolomide and thalidomide provided disease stabilization in a subset of patients with advanced leiomyosarcoma. We hypothesize that temozolomide is the active agent in this regimen, and should be further studied.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-10448291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-10623706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-12181401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-12947072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-14584078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-14669291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-15661684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-15758010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-15916799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-16134177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-16421420,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-16750621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-1998993,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-2491883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-3585441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-769974,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-8315424,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-8499135,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19043564-9332462
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:status |
PubMed-not-MEDLINE
|
|
pubmed:issn |
1357-714X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
2008
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
412503
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
|
|
pubmed:publicationType |
Journal Article
|
